ANDREW S BOMBACK
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology NEW YORK, NY NPI 1013129816
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology NY Aurinia Pharma U.S., Inc. All categories
General Payments — all program years on this page
$76,796.23
- Category: General Payments
- Program years: PY2018–2024
- Record count: 76
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $15,123.68 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $14,760.00 | 5 |
| Food and Beverage | $363.68 | 3 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Aurinia Pharma U.S., Inc. | $9,538.13 | 5 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,380.00 | 1 |
| Apellis Pharmaceuticals, Inc. | $1,080.00 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $125.55 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1086776585 | Novartis Pharmaceuticals Corporation | $125.55 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1118835671 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,380.00 | 09/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1150676775 | Aurinia Pharma U.S., Inc. | $124.80 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1150676777 | Aurinia Pharma U.S., Inc. | $3,600.00 | 04/05/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1150676779 | Aurinia Pharma U.S., Inc. | $2,100.00 | 06/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1150676781 | Aurinia Pharma U.S., Inc. | $113.33 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1150676783 | Aurinia Pharma U.S., Inc. | $3,600.00 | 11/21/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1154016625 | Apellis Pharmaceuticals, Inc. | $1,080.00 | 10/25/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.